Evidence map›Paper›PMID 38969503›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024

Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.

Barin Feroz, Teresa L Pan, Katharina Leitner, Christoph Ebner, Katharina Steger, Wanja Kildal, Gunnar Kristensen, Alain Gustave Zeimet, Hubert Hackl, Heidi Fiegl and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Barin Feroz *Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0009-0001-5064-1397
Teresa L Pan *Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0009-0004-2101-0811
Katharina LeitnerDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
Christoph EbnerDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
Katharina StegerDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
Wanja KildalInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Gunnar KristensenInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Alain Gustave ZeimetDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
Hubert HacklBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Heidi FieglLaboratory for Clinical Biochemistry, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
Christian MarthDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
Verena WieserDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria verena.wieser@i-med.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveImmune checkpoint inhibitors have recently demonstrated benefit in patients with advanced and recurrent endometrial carcinoma. This retrospective study investigated immune checkpoint molecules in endometrial carcinoma as they pertain to the molecular subtypes, clinical outcomes, and predictive value.

methodsTumoral RNA expression of genes controlling the immune checkpoint, programmed cell death 1 (PD1, encoded by

results

conclusionsTumoral gene expression controlling the PD1 immune checkpoint, particularly expressed in "hot tumors", predicted recurrence-free, disease-specific, and overall survival in patients with endometrial carcinoma in two independent cohorts. Evaluation of these genes could be used to stratify patients who qualify for immune checkpoint inhibitors, which warrants prospective clinical trials.

Indexed as

Biomarkers, TumorEndometrial NeoplasmsProgrammed Cell Death 1 ReceptorAdultAgedB7-H1 AntigenFemaleHumansInterferon-gammaMiddle AgedPrognosisRetrospective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanInterferon-gammaPDCD1 protein, humanProgrammed Cell Death 1 ReceptorEndometrial NeoplasmsGynecologyUterine Cancer

Identifiers

PMID38969503
PMCPMC11671916

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.